Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells

Cell Biology and Toxicology

Volumn 29, Issue 4, 2013, Pages 303-319

  Castillo Sanchez, Rocio ^a   Villegas Comonfort, Socrates ^b   Galindo Hernandez, Octavio ^b   Gomez, Rocio ^a   Salazar, Eduardo Perez ^b  

^a CINVESTAV IPN AP 14 740   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

B a P; Breast cancer; FAK; Migration

Indexed keywords

BENZO[A]PYRENE; FOCAL ADHESION KINASE; GELATINASE A; GELATINASE B; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN TYROSINE KINASE; VITRONECTIN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL MIGRATION; CELL STRAIN; CELL STRAIN MCF12A; CELL STRAIN MDA MB 231; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

RODENTIA;

BENZOPYRENES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRIN ALPHAVBETA3; LIPOXYGENASE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84883222282     PISSN: 07422091     EISSN: 15736822     Source Type: Journal    
DOI: 10.1007/s10565-013-9254-1     Document Type: Article

References (67)

1. Angus WG, Larsen MC, Jefcoate CR. Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status. Carcinogenesis. 1999;20:947-55.
2. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16:368-77.
3. Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest. 2001;107:1339-45.
4. Cavalieri E, Rogan E, Sinha D. Carcinogenicity of aromatic hydrocarbons directly applied to rat mammary gland. J Cancer Res Clin Oncol. 1988;114:3-9.
5. Charles GD, Bartels MJ, Zacharewski TR, Gollapudi BB, Freshour NL, Carney EW. Activity of benzo[a]pyrene and its hydroxylated metabolites in an estrogen receptor-alpha reporter gene assay. Toxicol Sci. 2000;55:320-6.
6. Christou M, Savas U, Spink DC, Gierthy JF, Jefcoate CR. Co-expression of human CYP1A1 and a human analog of cytochrome P450-EF in response to 2,3,7,8-tetrachloro-dibenzo-p-dioxin in the human mammary carcinoma-derived MCF-7 cells. Carcinogenesis. 1994;15:725-32.
7. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387-92.
8. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621-30.
9. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15:1163-9.
10. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252-7.
11. Egan C, Pang A, Durda D, Cheng HC, Wang JH, Fujita DJ. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene. 1999;18:1227-37.
12. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
13. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003;20:203-13.
14. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004;48:411-24.
15. Gao A, Liu BC, Huang CS, Shi XL, Jia XW, You BR. Ye M [ERK and JNK/AP-1 pathways involved in benzo(a)pyrene induced cell cycle changes in human embryo lung fibroblasts]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006;24:72-6.
16. Goel HL, Languino LR. Integrin signaling in cancer. Cancer Treat Res. 2004;119:15-31.
17. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010;223:14-26.
18. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816-26.
19. Hancock CN, Macias A, Lee EK, Yu SY, Mackerell Jr AD, Shapiro P. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem. 2005;48:4586-95.
20. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996;27:1695-701.
21. Hauck CR, Hsia DA, Ilic D, Schlaepfer DD. v-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion. J Biol Chem. 2002;277:12487-90.
22. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003;160:753-67.
23. Kamaraj S, Anandakumar P, Jagan S, Ramakrishnan G, Devaki T. Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9. Eur J Pharmacol. 2010;649:320-7.
24. Ke Z, Lin H, Fan Z, Cai TQ, Kaplan RA, Ma C, et al. MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. Int J Cancer. 2006;119:8-16.
25. Klampfl T, Bogner E, Bednar W, Mager L, Massudom D, Kalny I, et al. Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in colorectal cancer cells. Exp Cell Res. 2012;318:768-78.
26. Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol. 2005;18:1289-94.
27. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5:127-35.
28. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67-8.
29. Liu B, Khan WA, Hannun YA, Timar J, Taylor JD, Lundy S, et al. 12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. Proc Natl Acad Sci USA. 1995;92:9323-7.
30. Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol Chem. 2006;387:1209-13.
31. Luo M, Guan JL. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett. 2010;289:127-39.
32. Mastrangelo G, Fadda E, Marzia V. Polycyclic aromatic hydrocarbons and cancer in man. Environ Health Perspect. 1996;104:1166-70.
33. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010;16:3526-32.
34. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle. 2009;8:1168-75.
35. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26:3227-39.
36. Meng D, Lv DD, Zhuang X, Sun H, Fan L, Shi XL, et al. Benzo[a]pyrene induces expression of matrix metalloproteinases and cell migration and invasion of vascular smooth muscle cells. Toxicol Lett. 2009;184:44-9.
37. Miller ME, Holloway AC, Foster WG. Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output. Clin Exp Metastasis. 2005;22:149-56.
38. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 1997;57:1554-60.
39. Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Martinez-Orozco R, Salazar EP. Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway. Int J Biochem Cell Biol. 2010;42:306-17.
40. Nony PA, Kennett SB, Glasgow WC, Olden K, Roberts JD. 15S-Lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK. J Biol Chem. 2005;280:31413-9.
41. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003;116:1409-16.
42. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol. 1997;9:187-92.
43. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000;19:5606-13.
44. Phillips DH. Polycyclic aromatic hydrocarbons in the diet. Mutat Res. 1999;443:139-47.
45. Piomelli D. Arachidonic acid in cell signaling. Curr Opin Cell Biol. 1993;5:274-80.
46. Pliskova M, Vondracek J, Vojtesek B, Kozubik A, Machala M. Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events. Toxicol Sci. 2005;83:246-56.
47. Radtke S, Milanovic M, Rosse C, Rycker M, Lachmann S, Hibbert A, et al. ERK2 but not ERK1 mediates HGF-induced motility in non small cell lung carcinoma cell lines. J Cell Sci. 2013;126(11):2381-9.
48. Rajah TT, Pein KJ, Du N, Serret CA, Drews NR. Physiological concentrations of genistein and 17beta-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Anticancer Res. 2012;32:1181-91.
49. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-310.
50. Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, et al. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis. 2000;21:1281-9.
51. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002;80:239-56.
52. Savas U, Bhattacharyya KK, Christou M, Alexander DL, Jefcoate CR. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression. J Biol Chem. 1994;269:14905-11.
53. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta. 2001;1540:1-21.
54. Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta. 2004;1692:77-102.
55. Serna-Marquez N, Villegas-Comonfort S, Galindo-Hernandez O, Navarro-Tito N, Millan A, Salazar EP. Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells. Cell Oncol. 2013;36:65-77.
56. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2:249-56.
57. Siriwardhana N, Wang HC. Precancerous carcinogenesis of human breast epithelial cells by chronic exposure to benzo[a]pyrene. Mol Carcinog. 2008;47:338-48.
58. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006;8:R20.
59. Spink BC, Pang S, Pentecost BT, Spink DC. Induction of cytochrome P450 1B1 in MDA-MB-231 human breast cancer cells by non-ortho-substituted polychlorinated biphenyls. Toxicol In Vitro. 2002;16:695-704.
60. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res. 2005;25:79-83.
61. Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, et al. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem. 1996;271:28324-30.
62. Watermann DO, Gabriel B, Jager M, Orlowska-Volk M, Hasenburg A, zur Hausen A, et al. Specific induction of pp 125 focal adhesion kinase in human breast cancer. Br J Cancer. 2005;93:694-8.
63. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004;14:473-86.
64. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069-79.
65. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67-78.
66. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009;28:35-49.
67. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011;63:610-5.